Clinical Cancer Drugs

Dr. Urban Emmenegger obtained his medical degree from the University of Bern/Switzerland, followed by training in Internal Medicine and Medical Oncology, and research training in tumor biology, with special emphasis on tumor angiogenesis and metronomic chemotherapy. Currently, Dr. Emmenegger is appointed as Staff Medical Oncologist and Scientist at Odette Cancer Centre & Sunnybrook Research Institute, and is Assistant Professor in the Department of Medicine, all at the University of Toronto/Canada. Dr. Emmenegger is specialized in the treatment of advanced prostate cancer, a disease which is also at the center of his research interests. He is particularly interested in improving the use of metronomic chemotherapy for prostate cancer, in understanding therapeutic resistance, and identifying predictive biomarkers.

Professor Daiming Fan is the member and vice president of Chinese Academy of Engineering, foreign associate of the USA National Academy of Medicine, past president of Fourth Military Medical University, past president of Chinese Society of Gastroenterology, director of Xijing Hospital of Digestive Diseases, and director of State Key Laboratory of Cancer Biology. He is now the vice president of Chinese Anti-Cancer Association, and vice president of Asian Pacific Association of Gastroenterology. As the congress president, he successfully organized the GASTRO2013 (WCOG/APDW) in Shanghai. He was the first awardee of the Prize “French National Academy of Medicine-Servier”.

Dr Xueying Sun obtained MD and PhD from Shandong University in 1994. He is currently holding a professorial position at the Department of Surgery, the Affiliated Hospital of Harbin Medical University, and a position of Honorary Senior Research Fellow at Department of Molecular Medicine & Pathology, FMHS, University of Auckland. His present research and professional specialities include tumor hypoxia, cancer molecular targeted therapy, cellular signalling and non-coding RNAs. He was a winner of World Health Organization Fellowship (1999-2000) and Wellcome Trust Leave Fellowship (2001-2005). He has published over 200 research articles in peer-viewed journals including 120 articles in Science Citation Index journals. He is also a member of Editorial board of five academic journals, and a member of the review panels for National Natural Scientific Foundation, Ministry of Science and Technology and Ministry of Education of China.

Dr. Bocci is a professor of Pharmacology at the University of Pisa. He obtained the degree of Medicine (1995), the degree of Clinical Pharmacology (1999) and a PhD in Pharmacology (2003) from the University of Pisa. Dr. Bocci was post-doctoral fellow for 3 years at the University of Toronto. Dr. Bocci is PI of projects granted by international associations, foundations and pharmaceutical companies. He is member of ASCO and AACR. He is author of more than 130 scientific papers published on international journals, 11 chapters on books, and 5 patents. He is regional editor of Clinical Cancer Drugs from the foundation of the journal.

Dr. Yee obtained a medical doctorate (M.D.) and a doctorate (Ph.D.) in Molecular Biology from Cornell University. Currently, Dr. Yee is an Assistant Professor of Medicine in Hematology and Oncology in the Pennsylvania State University College of Medicine. He is also a medical oncologist in the PennState Cancer Institute, and an attending and consultant physician in the PennState Milton S. Hershey Medical Center. He has published extensively in basic, translational, and clinical sciences, including original research articles, review articles, book chapters, and clinical case reports. Dr. Yee is currently the Regional Editor of this journal (Clinical Cancer Drugs), published by Bentham Science Publishers.

Dr. Ahmed Mohammed Abu-Dief Mohammed did M.Sc. in Inorganic / Physical Chemistry from Chemistry Department, Faculty of Science, Sohag University, Sohag, Egypt in 2010. He obtained his Ph.D. in Bioinorganic / Physical Chemistry in 2013. Currently, he is a Lecturer in the Chemistry Department, Faculty of Science, Sohag University.

Nanotechnologists working on the interface of pharmacy, material science, drug delivery and virology. My group research is focused on the development of novel nanomaterials for cancer treatment and molecular imaging. The research is also focused on understanding the molecular mechanism underlying cancer progression by studying critical enzymes involved in exploring various therapeutics in vivo.

Dr. Chengfeng Bi, M.D., Ph.D. is a medical scientist at the University of Nebraska Medical Center, United States. His research field is hematological malignancies, especially in Non-Hodgkin’s Lymphoma (NHL). He has extensive experience in multi-disciplinary research including cancer biology and translational medicine. Dr. Chengfeng Bi’s current research focuses on identifying novel therapeutic strategies for hematological malignancies based on the understanding of oncogenic mechanisms.

Prof James CS Chim is a clinician scientist interested in the multiple myeloma. He is a Member of the International Myeloma Working Group, Executive Council Member of the Asian Myeloma Network, Founding member of the International Academy of Clinical Hematology (IACH) & Founding Chairman of the Hong Kong Society of Myeloma. He has published in excess of 240 articles in peer-reviewed journals including Blood, Leukemia and Journal of Clinical Oncology.

Dr. Jessica Dal Col is a Senior PostDoc Research Fellow at the Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno since October 2016. She obtained Biology Degree in 2003, PhD in Biochemistry, Molecular Biology and Biotechnology in 2007 (University of Ferrara, Italy), and specialization in Clinical Pathology (University of Chieti-Pescara, Italy, 2017). During her Ph.D. training she had an experience abroad in the lab of Prof. Michael Caligiuri (Director of the Comprehensive Cancer Center of the Ohio State University in Columbus). She worked for 14 years at the National Cancer Institute, C.R.O.-IRCSS in Aviano, Italy (2002-2016).

Assoc. prof. dr. farm. Danciu Corina (1984) received the degree in Pharmacy in 2008 at “Victor Babeş” University of Medicine and Pharmacy, Timisoara, Romania and PhD title in 2013- Doctorate conducted in co-between “Victor Babeş” University of Medicine and Pharmacy, Timisoara and the Goethe University Clinic of Frankfurt, Germany. From 2016 she is the Head of Department of Pharmacognosy at her Alma Mater University. She sustained her habilitation theses in 2018. Her competencies include pharmacognostical and physicochemical analysis of pure active compounds or total extracts; in vitro assays on cell culture (expertise in proliferation and apoptosis) and in vivo animal models (cancer and inflammation). High expertise regarding flavonoids and triterpenes. The total cumulated impact factor is over 90, h-index: 10- ISI Web of Science, 13-Google Scholar, she is the author of over 70 published articles on indexed international journals, she gained national and international prices for the presented research, peer-reviewer and guest editor for some specific magazines in the field, editor for international books, member in the editorial board of 7 international journals ,co-author of a patent.

Samuel Cos, M.D. in 1983 and Ph.D. in 1986, is Full Professor and Head in the Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, Santander, Spain. For over 30 years, Dr. Cos’s research has focused on the oncostatic actions of melatonin, particularly in breast cancer. He has published over 100 journal articles, book chapters and reviews on this topic. His research has been supported by Spanish and European funding agencies. He currently serves on the editorial boards of the Clinical Cancer Drugs, Journal of Tumor and Dataset Papers in Medicine: Oncology.

Zhijun Dai is focused on the research of breast cancer, single nucleotide polymorphisms, anticancer and pharmacological properties of natural compounds. He has published over 100 peer-reviewed articles in international journals. To date these publications have been cited over 1,100 times. In addition, he is an Editorial Board Member of some journals as well as a regular reviewer for over 20 clinical and scientific journals, and serves as a grant reviewer for China.

Antonello Di Paolo received his MD (1992) and degree in Pharmacology (2000) from the University of Pisa, Italy, while he gained his PhD (1997) at the Superior School of University Studies in Pisa. Currently, Antonello Di Paolo is associate professor of Pharmacology at the University of Pisa and physician at the Unit of Clinical Pharmacology and Pharmacogenetics, Civil Hospital, Pisa. His main research is focused on pharmacokinetics and pharmacogenetics of anticancer agents, with special interest in fluoropirimidines in colorectal cancers, small tyrosine kinase inibitors and immunomodulating agents in hematological malignancies. He is authors of more than 100 articles published on indexed international journals.

Dr. Q. Ping Dou is Professor of Oncology, Pharmacology and Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI. He obtained his B.S. degree in chemistry from Shandong University in 1981, Ph.D. degree in chemistry from Rutgers University in 1988, and postdoctoral training at Dana-Farber Cancer Institute and Harvard Medical School from 1988 to 1993. Dr. Dou has extensive experience in the fields of molecular targeting, drug discovery, chemoprevention, natural products, proteasome inhibitors, cell cycle and apoptosis, and has published ~222 peer-reviewed research and review articles, many of those in journals of the highest quality.

Dr. Shailendra Dwivedi, currently working as Assistant Professor in Department of Biochemistry, AIIMS Gorakhpur India. He has completed PhD thesis on “Correlation of IL-18 promoter gene polymorphisms and assessment of transcriptional factor (Nf-kB) expression in prostate carcinoma” from King George Medical University, Lucknow. During PhD he has been awarded with Senior Research Fellowship (Individual) from Indian Council of Medical Research, New Delhi for three years (March2010 – Jan 2013) and also completed Post-doctoral research was on “Dynamics of Breast Cancer Stem cells with oncogenic miRNAs (miR-10 a&b, miR-21, and miR-17), Tumour suppressor miRNAs (miR-200a &b, miR-205 and miR-145) and their significance in development, progression and metastasis of breast cancer”. Published more than 35 articles (PubMed indexed) and 9 International book chapters with reputed international publishers. He also has received many international young scientist awards from eminent international association like Asian Pacific Federation of Clinical Biochemistry (APFCB-2016), Korean Cancer Association (KCA-2016) and Multinational Association of Supportive Care in Cancer (MASCC-2017), Japanese Society of Medical Oncology(JSMO-2018). Currently, he is also serving as Associate Editor of Indian Journal of Clinical Biochemistry (PubMed-indexed) Journal and also actively involved in review board of Various National and International Journal.

Rajesh N. Gacche (Ph. D. LL. B.) is presently working as a Professor & Head, Department of Biotechnology of Savitribai Phule Pune University (Previous Pune University), India. Prof. Rajesh has an excellent track record of publications of over 104 research articles in journals of repute, 5 patents and also completed over dozens of research projects in the area of Biomedical Research in general and Cancer Biology in particular. He has visited countries like USA, China, Austria, Singapore etc. for collaborative research. Prof. Rajesh has a passion of teaching Biology by using a reductionist approach and linking it with evolving behavioral, adaptive, and pathophysiological concerns of human ailments.

Dr. Griffioen obtained his PhD in immunology and medicine from the Utrecht University, The Netherlands. He is Being trained and formally registered as an immunologist, dr Griffioen’s research interest is in vascular biology and angiogenesis. He is currently professor of experimental oncology and angiogenesis and is heading the Angiogenesis Laboratory at the VU University Medical Center in Amsterdam. Dr. Griffioen has published over 220 scientific publications, is inventor on 20 patents and is the founding Editor-in-Chief of the journal Angiogenesis (1997).

Chairman of department of biological sciences in Hyupsung University. Toxicology and Stem Cell Biology, Oncology, M.S. in Public Health and Ph.D. in Environmental and Reproductive Toxicology, 12 years of research experience in (in vitro and in vivo) toxicology of stem cell research Lab. (hepatotoxicity, neuronal toxicity, cardiac toxicity using primary human cells and human pluripotent stem cell-derived somatic cells etc), 8 years of postdoctoral training in Stem Cell & Tissue Regeneration Unit and developing theranostic anticancer drug in Korea University and 2 years of R&D manager in Nexcel Inc, specialized in hepatic, neural, and cardiac toxicity), and 9 years of academic and research experience in Korea Univ. as a research professor of Biotechnology (Stem cell technology, specialized in hepatic toxicity of cell- and mouse-based screening system).

Dr. James Ho is an Associate Professor and Honorary Consultant at the Department of Medicine, Queen Mary Hospital, The University of Hong Kong (HKU). He received his medical degree (M.B.,B.S.) in 1993 and M.D. in 2007 from HKU, with training in internal medicine and respiratory medicine. He is FCCP and FRCP (Edin, Lond and Glasg). Dr. Ho has an established track record in lung cancer research, and the areas of focus over the years include preclinical models, the role of antioxidants, epidemiology, diagnostics, and clinical trials. He has published more than 90 papers in peer-reviewed journals.

Dr. Sazzad M. Hossain is currently operating as the Chief Scientific Officer and Founder of InMed Pharmaceuticals Inc, Vancouver, BC. Since 2015, he is Scientific Advisor and Co-founder of Pramana Pharmaceuticals Inc, Vancouver, BC. Dr. Hossain obtained his PhD in Biology from the Department of Physiology and Nutrition, Moscow State Academy of Veterinary Medicine and Biotechnology, Moscow. He has Published 24 peer-reviewed research papers so far.

I received my PhD in Chemistry from CSIR-CIMAP. I worked on Indian medicinal plants with top notch safety standards, Structure Activity Relationship (SAR) and in-silico computational studies. The formulations were validated against cancer, malaria, filaria and tubercular assays. I started working as Post-doctoral researcher in Department of Pharmacology and toxicology, University of Kansas. I am currently involved in organic synthesis, lead identification, and characterization for their bio-availability against Alzheimer’s disease and diabetes. In silico virtual screening, pharmacophore query elucidation, QSAR, docking, ADME/T, mutation exercise are part of my research. Animal handling and their database has been credited to my ongoing work.

Prof. Michael Koutsilieriswas born in Piraeus, Greece (1954), and he graduated the Medical School of National & Kapodistrian University of Athens (1980). Then he was trained in "Endocrinology" at the Division of Endocrinology, Department of Medicine, Royal Victoria Hospital, McGill University, Quebec, Canada (1982-1987). There he obtained also his Ph.D degree at the Department of Experimental Medicine, McGill University (1987). He was appointed as a Research Associate, Department of Biochemistry & Molecular Biology, Faculty of Medicine, Sherbrooke University, Quebec, Canada and as an Assistant (1988), Associate and full Professor (1997) at the Faculty of Medicine, Laval University, Quebec, Canada.

I graduated from the University of Catania with honors; I received a PhD in Advanced Multidisciplinary Research in Transplantation. I am a Consultant in General Surgery at the Cannizzaro Hospital in Catania. I was a fellow at the Faculdade de Medicina De Marilia, Brazil and at the Advocate Christ Medical Center in Chicago. I am part of several research groups dealing with new surgical techniques and new materials. I am author of several publications and book chapters

Dr. Wei Li is a Professor from the Second Military Medical University. He obtained his PhD from the Chinese University of Hong Kong, and postdoctoral training in Hong Kong Polytechnic University, and then took the research assistant professor position in Tokyo Women’s Medical University from 2007. Since 2010, he works in the Second Military Medical University by the special talent program to set up a new nanomedical lab. His current research mainly focus on nano physical pharmaceutics and anti-tumor nanoimmunotherapy.

Dr. Limonta obtained a Degree in Pharmaceutical Chemistry and Technology and a Degree in Pharmacy from the University of Milano, Italy. She also holds a Postdoctoral Degree in Pharmacology and a Postdoctoral Degree in Experimental Endocrinology from the University of Milano, Italy. She has been Postdoctoral fellow in Biology of Reproduction at the Population Council, Center for Biomedical Research, New York (1983-1984). Currently, Dr. Limonta is Associate Professor of Applied Biology, at the University of Milano. She has published 90 scientific peer-reviewed publications, most of them in the field of molecular oncology. She is currently Editorial Advisory board Member of the journal 'Clinical Cancer Drugs'.

Dr. Paul Lockman is a Professor and the Douglas Glover Endowed Chair for Pharmaceutical Sciences at West Virginia University School of Pharmacy, as well as the Associate Director for Translational Research at the Mary Babb Randolph Cancer Center in the West Virginia Cancer Institute. Dr. Lockman specializes in the mathematical modelling of drug entry into brain. His work has led to an understanding of how the specialized vasculature of the brain limits chemotherapy from reaching brain metastases of breast cancer at effective concentrations.

Rama Rao Malla is currently working in the Department of Biochemistry, Cancer Biology Lab, GIS, GITAM University, Vizag, India . His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests reflect in his wide range of publications in various national and international journals.

Dr. Shigeo Masuda received his MD from the University of Tokyo in 1996, and PhD in Hematology/Oncology from the Graduate School of Medicine, University of Tokyo, Japan. He was an Assistant Professor and an Associate Professor at Jichi Medical University, Japan, from 2007 to 2012, and joined RIKEN CDB in 2011. He studied at the Belmonte Lab in the Salk Institute from 2012 to 2014. Currently, he is an Associate Professor of Cardiovascular Surgery in Osaka University, Japan. His interest is regenerative medicine using iPS-derived cells, including molecular targeted therapy for iPS-derived undifferenated cells to improve safety.

Dr. Albert Mellick is an Associate Professor in Medical Oncology, University of New South Wales (UNSW), and member of the Ingham Institute for Applied Medical Research. Dr. Mellick runs an Australian Research Council and National Medical Research Council funded lab, and he has authored many research publications focused on the understanding and treatment of cancer malignancy. Prior to his current appointment he has served as foundation Chair Pharmacology, Deakin University; foundation Griffith Medical Research College Fellow, and Research Fellow, Cold Spring Harbor Laboratories; where he developed methods in retro-viral delivery of inhibitory RNAs and published seminal papers on endothelial progenitors.

Oleksandr H. Minchenko (Alexander G. Minchenko – in USSR passport), PhD, DrSc, Professor, Corresponding member of the Ukrainian Academy of Sciences of Ukraine, DoB 1946. He worked at Institute of Endocrinology and Metabolism, Kyiv, Ukraine, Thomas Jefferson University (Philadelphia, USA) and up to now at Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine. As visiting scientist he worked at National Cancer Center, Japan, University Bordeaux 1, France, University of Duisburg‐Essen, Germany, and Institute of Biology Shandong Academy of Sciences, Jinan, China. Research interests: endoplasmic reticulum stress signaling and hypoxia in tumor growth and chemoresistance, in metabolic diseases, nanoparticles genotoxicity.

Dr. Partha Pratim Mitra is a visiting scientist Queensland University of Technology, TRI Campus, Brisbane, Australia (where he is involved in developing cancer cell lines with expression of recombinant proteins and further studying the function aspects). His achievements are (a) he developed a therapeutic model where CDK9 can be considered as a target for estrogen positive breast cancer (b) he identified a part of the complex as well as its inhibitors with therapeutic potential that regulates the expression of human c-Myb gene in breast cancer cell.

Prof. David Morales-Morales (B.Sc, 1992; M.Sc, México, 1995- Chemistry School of the Universidad Nacional Autónoma de México- UNAM; Ph.D, Essex University, UK, 1998; Posdoctoral Fellow, University of Hawaii at Manoa, USA, 1998-2001) takes its current position at the Instituto de Química, UNAM, México in 2001. He has published over 165 papers and 10 reviews in top JCR journals, and 11 book chapters. And has served as editor in chief of the books “The Chemistry of the Pincer Compounds” (2007) and “Pincer Compounds. Chemistry and Applications” (2018) edited by Elsevier (Netherlands), that overall have been cited over 4600 times, h=32.

Gianfranco Natale is associate professor of Human Anatomy at the University of Pisa. He obtained the degree of Medicine (1990) and the degree of Clinical Pharmacology (2004) from the University of Pisa. He participated in the organization of scientific congresses and exhibitions. He is author of more than 80 scientific papers published on international journals, 20 chapters on books, and 1 book. He is director of the Museum of Human Anatomy “Filippo Civinini” of the University of Pisa and he is interested in the history of medicine.

Dr. Newton graduated from SUNY Buffalo with High Honors in Psychology, before pursuing a Masters Degree in Cancer Chemotherapy and Pharmacology from the Roswell Park Cancer Institute. He then entered the SUNY Buffalo School of Medicine, graduating in 1984. After an Internship in Internal Medicine within the SUNY Buffalo Health System, he was trained in Neurology at the University of Michigan Medical Center in Ann Arbor, MI, followed by a Fellowship in Neuro-Oncology at the Memorial Sloan-Kettering Cancer Cancer (MSKCC). At MSKCC, he trained under the guidance of Drs. Jerome Posner and William Shapiro. After the completion of his Fellowship at MSKCC, Dr. Newton joined the Faculty in Neurology at the Ohio State University Medical Center and James Cancer Hospital, establishing a Division of Neuro-Oncology within the Department of Neurology in the summer of 1990. Dr. Newton achieved the rank of Full Professor of Neurology with tenure, and was bestowed the Esther Dardinger Endowed Chair in Neuro-Oncology in 2003. His interests include clinical Neuro-Oncology, molecular chemotherapy of brain tumors, molecular biology of brain tumors, and clinical trials. After retiring from OSUMC in 2015, he has since become the Director of the Neuro-Oncology Center for the Advent Health Cancer Institute and Advent Health Orlando campus. He has published more than 220 articles and book chapters, and is the author or co-author of 10 books in the fields of Neurology and Neuro-Oncology.

Prof. Patrycja Nowak-Sliwinska joined the School of Pharmaceutical Sciences of the University of Geneva in June 2016. She is a head of Molecular Pharmacology Group and with her team she currently works, in a close collaboration engineers and with clinical partners, on personalized optimization of multi-drug combinations for cancer treatment.

Bulent Ozpolat earned his M.D. in 1989 from Dokuz Eylül University in Izmir, Turkey. He moved to Houston in 1994 and enrolled in The University of Texas Graduate School of Biomedical Sciences at Houston where he obtained a Ph.D. in Immunology (1999), In the past five years, Dr. Ozpolat has contributed to more than 20 manuscripts in peer-reviewed journals focusing on autophagic cell death (Type II programmed cell death), differentiation therapy, signal transduction and the development of targeted therapies. He has made significant contributions to the field through describing a new posttranscriptional mechanism of cell differentiation induced by retinoids; the mechanisms of autophagic cell death in breast and pancreatic cancers cells; and novel tumor-targeted carrier systems for siRNA, peptides for cancer therapy.

Yan Peng, MD, PhD is a Professor of Pathology of UT Southwestern Medical Center, USA. She is an active member of the Faculty Promotion and Tenure Committee. She served as Medical Directors of Diagnostic Immunohistochemistry Laboratory and Image Analysis and FISH Laboratory for about 10 years.Dr. Peng authored more than 90 peer-reviewed articles and book chapters, mainly in the field of breast cancer research. She served as an Editor for a textbook entitled Practical Breast Pathology (Springer). She has served as an editorial board member for multiple scientific journals including Human Pathology, Seminars in Diagnostic Pathology. As co-investigator, she has participated in many National Cancer Institute (NCI) Breast and Gynecologic cancer clinical trials and has served as an investigator for NCI Cancer Therapy Evaluation Program. She is a past President of the North Texas Society of Pathologists.Dr. Peng completed her research fellowship, Pathology Residency and Fellowship at Mayo Clinic, University of Pittsburgh Medical Center and Harvard Medical School.

Dr. Alfredo Procino has devoted a large part of his research activity studying the role of HOX genes in the control of human solid tumors. Currently, his scientific interest concerns the molecular mechanisms involved in the control of the cell memory program (with a special focus on cancer cells). He obtained his PhD in Clinical and Experimental Medicine (2014), Department of Neuroscience, Medical School "Federico II”, Naples. Dr. Procino has published around 33 journal articles and 3 books.

I am working on the protein modification and human diseases, and we are using cell, animal model and disease specimens, integrated with molecular, cellular and developmental biology and pathology knowledge and methods, to study the regulatory mechanism of protein SUMO modification (SUMOylation) mediated cell signaling transduction, and its role in the development of human diseases, and provide theoretical basis for medical treatment.

Dr. Md. Atiqur Rahman is seving as a Professor at Islamic University, Kushtia-7003, Bangladesh. He completed his Master of Science from the University of Rajshahi, Bangladesh and he further obtained PhD Daegu University, Korea. His research interest include Natural Products Chemistry,Bio-Organic and Medicinal Chemistry, Biotechnology (Isolation and characterization of medicinally important compounds from plants and microorganisms such as bacteria and marine fungi, Analyses of essential oils and screening of their biological and pharmacological activities). He has contributed his work in different national and international journals.

I want to say that, I undersigned and awarded my PhD degree under the department of Medicinal Chemistry of Jamia Hamdard (Hamdard University), New Delhi, India. My PhD research work was focused on ˜Studies on some heterocyclic compounds as potential anticancer agents embrace the design (rationale and computational) and synthesis of more than hundred new chemical entities by multistep reactions for each of the specified moieties with a prime objective to perform anticancer screening. My research work has been recognizing in the National Science Day in Jamia Hamdard, New Delhi, India. The contribution and so far of my research has been published more than fifty publication and review article with high impact and reputed peer viewed journals. I also awarded many travel and poster award from ICMR, DST, CSIR, Eurotox and IUTOX for the presenting research work abroad. I have been visited 5 countries with the contribution of research activity. I two times GATE (Graduate Aptitude Test in Engineering) exam qualified with 98.15 percentile. I have been worked as Project Fellow, JRF and SRF, University Grant Commission, Government of India. Recently, I was awarded Young Scientist, from Science & Engineering Research Board (SERB) under Department of Science & Technology (DST), Government of India, New Delhi [Registration No. SERB/LS-1030/2013] on the project entitled as “Design and development of Cdc7 kinase inhibitors by targeting the ATP and Dbf4 binding sites of Cdc7 kinase protein”. Currently, I am working as Assistant Professor and involved as head of scientific research activity at College of Dentistry and Pharmacy, Buraydah Colleges, Al-Qassim, Kingdom of Saudi Arabia.

Dr. Ramin Rezaee is currently an Assistant professor at School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. He received Doctor of Pharmacy (PharmD) degree from Mashhad University of Medical Sciences, Iran in 2007 and PhD in Toxicology from Mashhad University of Medical Sciences, Iran in 2014. He has numerous publications to his credit.

Ahmad Salimi is an assistant professor of toxicology in the Department of Pharmacology and Toxicology at the Ardabil University of Medical Sciences. He studied Toxicology in Ahvaz (Ahvaz Jundishapur University of Medical Sciences) and did his PhD in Tehran (Shahid Beheshti University of Medical Sciences). His research focuses on the selective toxicity new drugs on cancer cell, the interface between chemical agents and immune system, mechanistic toxicology using isolated cells and mitochondria and also cell culture. A special interest is the using of mitochondria for therapy various diseases. He (co-)authored over 60 papers and 6 book chapters

Professor in Medicinal Chemistry University of Basilicata, Department of Science.1989 University Louis Pasteur in Strasbourg (F) (DEA) - Pharmacologie et Pharmacochimie, option : Pharmacochimie. Supervisors prof.C.G.Wermuth and J.J.Bourguignon. 1991-1993: Fellow of the Pharmaceutical Industry -Servier in Paris and later the University of Caen (F). Co-autor: 114 (publications, 6 Patent, ecc.). Research Interest: Carbazoles, Organometallic compounds, Pyrazoles, Suzuki reaction, Design, Synthesis and biological studies and understanding of the mechanisms of action of new therapeutic molecules for: cancer, neurodegenerative diseases, antimicrobial agents.

Suzy Scholl is a cancer specialist for women. She is a doctor at the Institut Curie and coordinates the European Rational Molecular Assessment Innovative Drug Selection (RAIDs) project on molecular analysis and the search for new therapeutic strategies.

Received her MD from Necker Hospital (Paris Descartes University, France) and her PhD in Molecular and cellular Biology from Pierre and Marie Curie University (Paris, France). After working in Molecular and Biological Pharmacology in Gustave-Roussy Institute (Villejuif, France), she obtained a position as a research scientist at CNRS. She joined Saint-Louis Hospital (Paris, France) in 1998 where she became a team leader as a Research Director working on the pharmacological and physiological regulation of the telomerase expression and activity in an INSERM Unit. She joined Paris Descartes University in 2010 where she became the head of INSERM UMR-S 1007 named "Cellular Homeostasis and Cancer".

Dr. Tang obtained his Medical Doctor Degree and Ph.D. in Pathogen Biology from Tianjin Medical University, and gained postdoctoral training in Harvard University and HHMI. He was a faculty member in Harvard Medical School and Fudan University. Currently Dr. Tang is a Professor and Chair of Tianjin Life Science Research Center and Department of Pathogen Biology, Tianjin Medical University. Dr. Tang has focused on the regulation of non-coding RNA on tumorigenesis and viral proliferation. He has published more than 100 research articles and served as an editor of more than 10 journals.

Dr. Yusuf TUTAR currently continues his research in University of Health Sciences, Faculty of Pharmacy, Department of Basic Pharmaceutical Sciences, Division of Biochemistry- Mektebi Tıbbiye-i Sahane Turkey. He is also the head of Molecular Medicine Program. He obtained his M.Sc. and Ph.D. at Oregon State University and Texas Tech University respectively. He pursued his postdoctoral study at National Institutes of Health (NIH/NIDDK), USA. His research focuses on Biochemistry, Biophysics, Genetics, and Molecular Biology with specialization in the fields of drug design, protein structure-function, protein folding, prion, microrna, pseudogenes, molecular cancer, epigenetics, metabolites, proteomics, genomics, protein expression and characterization by spectroscopic and calorimetric methods.

Dr. Rumiana Dimitrova Tzoneva is affiliated with Institute of Biophysics and Biomedical Engineering-BAS. Since last three years, she is a Professor in Institute of Biophysics and Biomedical Engineering-BAS. She obtained her MSc in Molecular and Functional biology from Sofia University, Bulgaria. Later, Dr. Tzoneva obtained the qualification of PhD (Biotechnology-biomaterials) from the Natural-Mathematics faculty, Potsdam University, Berlin, Germany.

Dr Usui is currently an associate professor at the Department of Ophthalmology in Tokyo Medical University Hospital, Japan, and visiting associate professor at the Scripps Research Institute in San Diego, USA. He is particularly interested in ocular tumors and involved in the treatment of ocular tumors. In his university hospital, He perform over 700 surgeries a year (including vitrectomies, cataract surgeries, and ocular tumor surgeries), which leaves very little time for in-depth research. He has received numerous honors and awards for his research endeavors on American Academy of Ophthalmology. Dr Usui has published over 130 peer reviewed articles in the United States and in international journals, four books on ophthalmic diseases.

Dr. P.J. Vlachostergioshas a degree in Medicine and a Ph.D. in cancer cell biology. He completed his residency at New York University School of Medicine, NYU Langone Hospital-Brooklyn and continued his training at the Division of Hematology/Oncology, Weill Medical College of Cornell University, New York. His studies have focused on: a) cachexia and immune responses in lung cancer b) proteasome inhibition in glioma c) neuroendocrine differentiation of prostate cancer d) DNA repair gene mutations in urothelial cancer e) chemotherapy and immunotherapy resistance in urothelial carcinoma. He is author, reviewer and editorial board member of several international peer-reviewed journals.

Lu Xie obtained her M.D. and Ph.D. degree from Xiang-Ya Medical College of Central South University, China. She was a postdoctoral Research Fellow in Vanderbilt University, USA for five years. She is currently the Vice Director of Shanghai Center for Bioinformation Technology. She published more than 140 papers on international and Chinese journals. She is a committee member for Shanghai Society of Bioinformatics. Her work directions involve omics data analyses and integration; tumor neoantigen and immunotherapy; clinical decision making modeling.

Dr. Feng Yang was associate researcher of Brookhaven national lab in USA after graduated from Chinese academy of sciences. He is primary investigator of State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources. He has been interested in design anticancer metal drug based on the protein structure, protein-based drug delivery systems, and multi-drug combination therapy of cancer.

Xiuping Yu graduated from Nankai University and got her Ph.D. degree from Dalian Medical University, China. He was trained in Dr. Robert Matusik’s laboratory at Vanderbilt in the area of molecular and cancer biology with particular expertise in the transcriptional regulation of prostatic genes and the use of genetically engineered mouse models as well as tissue recombination approach in PCa research. He is currently Assistant Professor of Biochemistry & Molecular Biology, LSU Health Sciences Center Shreveport. He research interest focuses on studying the mechanisms through which PCa become castration resistant and the development of neuroendocrine PCa.

Dr. J. Gasparotto graduated in Physical Education from Universidade Luterana do Brasil-ULBRA. His Post-graduation was in Exercise Physiology and Training Prescription from Gama Filho University of Rio de Janeiro. Later, he did Master and PhD in Biological Sciences - Biochemistry by Federal University of Rio Grande do Sul-UFRGS. Currently, he is linked with the National Postdoctoral Program of CAPES and collaborator of the Department of Biochemistry of UFRGS. He has experience with several experimental models, including rodents, cell culture and clinical studies.

Dr. Rajeev Mishra is Assistant Professor in the Department of Biosciences at Manipal University Jaipur, India. Dr Mishra, prior to Joining Manipal University Jaipur, was Project Scientist at Samuel Oschin Cancer Center, Cedars Sinai Medical Center, Los Angeles, California, USA. After finishing Ph.D. in 2007, he joined Department of Cancer Genetics, Nihon University School of Medicine, Tokyo, Japan as the post-doctoral fellow. Dr Mishra has published several research papers in almost all top cancer journals. He has more than 16 years of experience in cancer drug discovery research and therapeutic resistance.

Dr. Motadi is an academic cancer researcher with over 17 years postdoctoral experience encompassing undergraduate and postgraduate teaching and supervision with extensive research experience. Sustained international scientific standing, evidenced by sustained publications in high impact international journals. Currently he is National Research Foundation (NRF) rated scientist. His research background are in a highly specialized area of molecular oncology, new drug target identification and apoptosis. The research interest mainly using new or old small molecule targets to restore the cellular molecular machinery in cancer cell.

I earned my Ph.D from the National Centre for Cell Science (Pune University), Pune, India. I am pursuing postdoc research associate in the Department of Radiation Oncology, Washington University in St. Louis. I am serving as a board Member of various scientific journals and dynamically serving as a reviewer in several peer reviewed scientific journals. I am actively engaged in cancer research and has published more than 15 peer review articles in international journals. I also participated and presented my research work in many national and international meetings. My area of research includes cancer cell biology, metabolism, obesity, miRNA and natural products biology in relation with various types of cancers.

Dr. Achuthan Raghavamenon is currently working as Associate professor Biochemistry at Amala Cancer Research Centre. He received PhD in Biochemistry from Mahathma Gandhi university, Kerala Inda in 2000 and thereafter has 19 years of research experience in the fields of oxidative chemistry and biology, degenerative diseases (atherosclerosis, neurodegeneration, and Cancer), plant molecular biology (PR proteins and DNA-based markers). His major interest is oxidized lipids and degenerative diseases. He has credited with more that 40 research paperes in the national and international peer reviewed journals. His current research attemt to identy fy the role of oxidized lipids in cancer development.

Dr. Rochani is presently working as a postdoctoral research fellow at Department of Pharmaceutical Science, Thomas Jefferson University, Philadelphia, USA. He was awarded Japanese Govt. (MEXT) fellowship for pursuing Ph.D. in Bio Nano Science from Toyo University, Japan. He has published many research papers and given scientific presentations at various international conferences in the field of drug development and delivery using nanotechnology and mass spectrometry. He is a reviewer for many peer-reviewed high impact scientific journals. He has significant expertise in formulation and bioanalytical chemistries for drug development. His work focuses on developing polymeric controlled drug delivery systems for pathologies like cancer.

Małgorzata Rogalinska completed Her PhD degree at the Department of cytobiochemistry, Faculty of biology and Environmental Protection, University of Lodz, Poland. Since year 2011 till 2013 she was a principal investigator of grant entitled: “Personalized therapy for chronic lymphocytic leukemia”. Since April 2017 she became Associate Professor at the department of Cytobiochemistry, University of Lodz, Poland. She has published more than 20 papers in reputed journals or presented more than 50 posters on domestic or international conferences. She was also serving as reviewer in many international journals (eg. Spandidos Publications, Bentham Science or Elsevier).

Dr. Mirela Sedic is an Associate Professor at the University of Rijeka Department of Biotechnology in Croatia. She is author/co-author of more than 30 scientific publications in peer-reviewed journals including high-impact journals such as Molecular Cancer, The Journal of Pathology, Molecular Cancer Therapeutics, Journal of Medicinal Chemistry, and Cancer Treatment Reviews. She is also co-author of book chapters in Drug Discovery, Personalized Medicine: A New Medical and Social Challenge (Springer International Publishing, 2016), and has one international patent (WO/2010/052510). Her work has been cited 755 times (h-index 14; i10-index 18). Dr. Sedic has also reviewed several international scientific journals in the past.

I have been working in the field of translational medicine, inflammation, and redox biology in diseases like diabetes mellitus and cancer from the last 10 years. My research focuses on 1) determine the therapeutic efficacy of natural and chemically synthesized novel drugs in diabetes and cancer prevention, 2) study the molecular and cellular mechanism of combine treatment of chemotherapy/immunotherapy/ radiotherapy in drug-resistant head and neck cancer, 3) develop ex vivo methods using patient-derived organoids (PDOs) to test the sensitivity and identify optimum treatment dose of a variety of cancer therapies for Head and Neck Cancer patients, which minimizes the use of experimental animals and allows for selection of therapies that fit the molecular features of individual patients fitting with the current needs of precision medicine, and 4) study the redox mechanisms of sepsis, a deadly disease that currently lacks treatment.

Dr. Norbert Sule earned his MD and Ph.D degree from the Medical School at University of Pecs, Pecs, Hungary. He is an associate Professor at the Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo NY, USA. He is serving as a board Member of various scientific journals and dynamically serving as a reviewer in several peer reviewed scientific journals. Dr. Sule is actively engaged in cancer research and has published more than 25 peer review articles in international journals. He also participated and presented his research work in many national and international meetings. His area of expertise includes GU, Head and Neck, Soft tissue and Neuropathology.

Dr. Xu Tian is a nurse practitioner interested in the digestive cancers, evidence synthesis and translation, evidence-based nursing practice, psychosocial rehabilitation for oncology and TMC nursing techniques. He holds a Master of Nursing from Tianjin University of Traditional Chinese Medicine, and a Bachelor of Nursing from Northwest Minzu University.He is a standing committee member of the Rehabilitation Association of China Anti-Cancer Association, Member of the Precision Oncology Association of WFCMS, Member of Oncology Rehabilitation Association of China Rehabilitation Association & Youth Member of Translation Medicine Association of Chinese Society of Microcirculation. He has published in excess of 80 articles in peer-reviewed journals including Alternative Therapies in Health and Medicine, Lancet, Critical Care, Frontiers in Oncology, Frontiers in Pharmacology, Frontiers in Medicine, Medical Oncology, Journal of Wound Care and British Journal of Surgery.

Dr. Yang is an Associate Professor, Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Key Laboratory of Reproduction and Genetics in Ningxia. Ningxia Medical University, Yinchuan, China.He received his PhD degree from Northwest &F University, and Post-Doctoral Research in The Chinese University of HongKong, visiting scholar in Bio-X research College of Shanghai Jiaotong University. His Research interests are Focus on cell signaling pathways in the regulation of ovarian cell survival, apoptosis, and related reproductive cancer. And all the research works are supported by two National Natural Science Foundation of China (NSFC).

Dr. Yarla completed PhD in the field of Cancer Therapeutics. Currently working as post-doctoral scientist and active member of American Association for Cancer Research and American Society for Pharmacology and Experimental Therapeutics. He published more than 100 articles in reputed peer reviewed journals with more than 1500 citations.

Eugenia Yiannakopoulou: Surgeon; Endocrine Surgeon; Breast Surgeon; Pharmacologist. Current position: Faculty in the Department of Biomedical Scineces, Faculty of Health and Caring Professions, ,University of West Attica, Athens, Greece; Director of her own private medical practice. Titles: Ptychio of medicine; MSc Minimally Invasive Surgery; MSc Medical Biology; MSc Biostatistics; PhD Pharmacology; University Diploma in Breast Diseases University of Strasbourg, France; University Diploma of Laparoscopic Surgery University of Strasbourg, France. University Diploma of Endocrine Surgery University Pierre et Marrie Currie Paris, University Diploma in Targeted Biotherapeis of Inflammatory and Autoimmune Diseases, University of Montpellier, University Diploma in Inflammatory Bowel Diseases Medical School University Pierre et Marie Currie Paris.

Dr Yu completed her PhD at Faculty of Medicine, University of Sydney, Australia in experimental therapeutics for cancer. She then pursued postdoctoral training at the Richard W. TeLinde Gynecologic Pathology Laboratory, Johns Hopkins University School of Medicine, USA with a focus on understanding the treatment for recurrent ovarian tumour. She heads the Oncology Therapeutics Research Group at Curtin Health and Research Institute (CHIRI) and holds a Senior Research Fellow position at the School of Pharmacy and Biomedical Sciences, Curtin University.

Dr. Si-he Zhang is an associate professor of school of medicine in Nankai University. He got his Ph.D. in Fourth Military Medical University and did postdoctoral training in Lund University Hospital. Dr. Zhang has focused on macromolecule drugs delivery and antibody-based cancer targeting therapy. His studies are supported by National Natural Science Foundation and National Key Technologies R & D Program of China. He has published dozens of peer-reviewed international papers (including Hepatology, PNAS, JBC, etc.) and obtained 12 invention patents. Dr. Zhang was also serving as reviewer for international journals (Elsevier, Springer, Wiley, Dove and Spandidos Press).